|
|
Volumn 14, Issue 2, 2005, Pages 297-298
|
|
The critical role of risk-benefit assessments in cancer prevention
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ALPHA TOCOPHEROL;
BETA CAROTENE;
CYCLOOXYGENASE 2 INHIBITOR;
FINASTERIDE;
NON PRESCRIPTION DRUG;
NONSTEROID ANTIINFLAMMATORY AGENT;
PLACEBO;
ROFECOXIB;
TAMOXIFEN;
ATHEROSCLEROSIS;
BLEEDING;
BREAST CANCER;
CANCER INCIDENCE;
CANCER MORTALITY;
CANCER PREVENTION;
CANCER RISK;
CANCER SCREENING;
CANCER SUSCEPTIBILITY;
CARDIOTOXICITY;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CEREBROVASCULAR ACCIDENT;
CLINICAL PRACTICE;
CLINICAL RESEARCH;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DRUG EFFICACY;
DRUG FATALITY;
DRUG SAFETY;
DRUG UTILIZATION;
EARLY DIAGNOSIS;
EDITORIAL;
FOLLOW UP;
GENETIC HETEROGENEITY;
HEART INFARCTION;
HIGH RISK POPULATION;
HUMAN;
HYPERLIPIDEMIA;
HYPERTENSION;
LUNG CANCER;
META ANALYSIS;
METHODOLOGY;
OUTCOMES RESEARCH;
PATIENT PARTICIPATION;
PRIORITY JOURNAL;
PROSTATE CANCER;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
RISK FACTOR;
SYSTEMATIC REVIEW;
THROMBOSIS;
UTERUS CANCER;
ANTICARCINOGENIC AGENTS;
CLINICAL TRIALS;
DRUGS, INVESTIGATIONAL;
HUMANS;
NEOPLASMS;
|
|
EID: 13944283316
PISSN: 10559965
EISSN: None
Source Type: Journal
DOI: 10.1158/1055-9965.EPI-14-2-EDA Document Type: Editorial |
|
Times cited : (7)
|
|
References (0)
|
